RGNX

Over the past six months, REGENXBIO's stock price experienced significant volatility, trending down by 9.93%. In August 2026, the company reported Q2 2026 earnings with an EPS of $0.43, exceeding analysts' expectations. Also in August 2026, REGENXBIO announced a regulatory update on RGX-121 for MPS II, which was followed by a 25% stock plunge after the FDA placed a clinical hold due to asymptomatic spine MRI findings in participants, described as disappointing and a potential delay. In August 2026, the Board of Directors was strengthened with the appointment of Greg Ciongoli. In July 2026, REGENXBIO priced an approximately $100 million public offering of common stock and pre-funded warrants at $9.00 per share to raise capital, leading to a 17% stock price drop due to dilution pressure. In May 2026, REGENXBIO announced topline results from the pivotal trial of RGX-202. In September 2026, the company presented positive three-year durability data for surabgene lomparvovec (ABBV-RGX-314) in diabetic retinopathy.